---
document_datetime: 2025-08-21 14:43:24
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/spevigo-epar-all-authorised-presentations_en.pdf
document_name: spevigo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8338583
conversion_datetime: 2025-12-31 04:57:53.816318
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form                   | Route of administration   | Immediate packaging        | Content (concentration)   | Pack size             |
|------------------|-------------------|------------|---------------------------------------|---------------------------|----------------------------|---------------------------|-----------------------|
| EU/1/22/1688/001 | Spevigo           | 450 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)               | 7.5 mL (60 mg/mL)         | 2 vials               |
| EU/1/22/1688/002 | Spevigo           | 150 mg     | Solution for injection                | Subcutaneous use          | pre-filled syringe (glass) | 1 mL (150 mg/mL)          | 2 pre-filled syringes |
| EU/1/22/1688/003 | Spevigo           | 300 mg     | Solution for injection                | Subcutaneous use          | pre-filled syringe (glass) | 2 mL (150 mg/mL)          | 1 pre-filled syringe  |